Diversity Supplement to Project 1

我们建议建立一个自身免疫卓越中心，将临床医生的努力， 人类免疫学家（基础和翻译），具有临床专业知识和研究的医生科学家 自身免疫、生物信息学家和老年组学/系统生物学家的经验。集合在一起， 该小组在临床试验方面具有广泛的背景，并在合并基础和临床试验方面有良好的记录。 科学该团队致力于将创新的治疗方法从实验室工作台带到他们的 病人的床边。在这种合作的设置，系统生物学的方法，提出了重点放在这两个 儿童和成人自身免疫性疾病。 该中心的目标是： 1)为了评估新型靶向治疗的疗效，2）使用 3）为了了解最近鉴定的T细胞亚群在 疾病的发病机制，和4）评估儿童和成人自身免疫性疾病的抗原特异性反应， 疾病 这些项目将使人们更好地了解特定自身免疫性疾病的发病机制， 使我们能够开发一种基于新的转录标记评估疾病活动的策略， 来鉴定自身抗原特异性免疫反应。 该中心将提供： 1)针对银屑病和皮肌炎特定细胞因子的创新临床试验。 2)皮肌炎、牛皮癣、狼疮和多发性硬化症生物标志物的发展。 3)皮肌炎治疗新靶点的鉴定。 4)开发检测自身抗原特异性免疫应答的试验。 5)人类自身免疫性疾病微阵列数据库的建立。

We propose to create an Autoimmunity Center of Excellence that will incorporate the efforts of clinicians, human immunologists (both basic and translational), physician-scientists with clinical expertise and research experience in autoimmunity, bioinformaticians, and geriomics/systems biologists. Together, the assembled group has an extensive background in clinical trials and a proven track record for merging basic and clinical science. This team is committed to bringing innovative treatments from the laboratory bench to their patients' bedside. Within this collaborative setting, a systems biology approach is proposed to focus on both pediatric and adult autoimmune diseases. The goals of the Center are: 1) To assess the efficacy of novel targeted therapies, 2) To develop simple and robust biomarkers using state-of-the-art genomic approaches, 3) To understand the role of recently identified T cell subsets in disease pathogenesis, and 4) To assess antigen-specific responses in pediatric and adult autoimmune diseases. These projects will provide a better understanding of the pathogenesis of specific autoimmune diseases and allow us to develop a strategy to assess disease activity based on novel transcriptional markers as well as to identify autoantigen-specific immune responses. The Center will deliver: 1) Innovative clinical trials targeting specific cytokines in psoriasis & dermatomyositis. 2) Development of biomarkers for dermatomyositis, psoriasis, lupus and multiple sclerosis. 3) Identification of novel therapeutic targets in dermatomyositis. 4) Development of assays to test autoantigen-specific immune responses. 5) Development of a unique microarray database of human autoimmune diseases.